会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 41. 发明公开
    • 인터루킨-1β 전환 효소의 아스파르테이트 에스테르 억제제
    • 白介素-1转化酶的ASPARTATE ESTER抑制剂
    • KR1020000049048A
    • 2000-07-25
    • KR1019997003117
    • 1997-10-09
    • 워너-램버트 캄파니 엘엘씨바스프 에스이
    • 알브레히트,한스,페.알렌,해미쉬,존브래디,케니쓰,데일캐프레이드,브래들리,윌리암길모어,존,로쥐하터,윌리암,글렌헤이스,쉐릴,진코스틀란,캐서린,로즈루니,엘리자베쓰,앤파라,킴벌리,수잔토마스,앤쏘니,제롬워커,니겔
    • C07C271/22
    • C07D207/08A61K38/00C07C233/47C07C233/51C07C271/22C07C275/16C07C311/03C07C311/06C07C311/19C07C317/04C07C317/44C07C323/52C07C327/32C07C2601/10C07C2602/10C07C2602/42C07D207/27C07D207/28C07D209/08C07D209/18C07D211/34C07D211/76C07D213/55C07D213/75C07D217/24C07D233/36C07D239/10C07D307/79C07D333/24C07D333/38C07D333/54C07K5/0202
    • PURPOSE: Provided are compounds which are inhibitors of interleukin-1ss converting enzyme. Also a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and a pharmaceutically acceptable composition containing the compound are provided. CONSTITUTION: Compounds which are inhibitors of interleukin-1 beta converting enzyme that have formula (I) wherein R¬1 is R¬3CO-, R¬3SO2-, each R¬a is independently hydrogen, C1-C6 alkyl, or -(CH2)n aryl; R¬2 is -(CRR)n-aryl, -(CRR)n-X-aryl, -(CRR)n-heteroaryl, -(CRR)n-X-heteroaryl, -(CRR)n-(substituted-heteroaryl), -(CRR)n-(substituted-aryl), -(CRR)n-X-(substituted-aryl), -(CRR)n-aryl-aryl, -(CRR)n-aryl-heteroaryl, -(CRR)n-aryl-(CH2)n-aryl, -(CRR)n-CH(aryl)2, -(CRR)n-cycloalkyl, -(CRR)n-X-cycloalkyl, -(CRR)n-heterocycle, -(CRR)n-X-heterocycle, -(CRR)n substituted heterocycle, each R is independently hydrogen, C1-C6 alkyl, halogen or hydroxy; X is O or S; R3 is C1 -C6 alkyl, aryl heteroaryl, -(CHR)n-aryl, -(CHR)n-heteroaryl, -(CHR)n-substituted heteroaryl, -(CHR)n-substituted aryl, -(CRR)nS(CH2)n-aryl, cycloalkyl, substituted cycloalkyl, heterocycle, substituted heterocycle, each R¬1 is independently C1-C6 alkyl, C1 -C6 alkylaryl, aryl, or hydrogen; each J is independently -C02R¬b, -CONR¬bR¬b, -SO2NR¬bR¬b, or -SO2R¬b; each R¬b is independently hydrogen, C1-C6 alkyl, aryl, substituted aryl; arylalkyl, heteroarylalkyl, substituted arylalkyl, or substituted heteroarylalkyl; R4 is hydrogen, C1-C6 alkyl, -phenyl, R6 is hydrogen, C 1 -C6 alkyl, -(CH2)n aryl, -(CH2)nCO2Ra, hydroxyl substituted C1-C6 alkyl, or imidazole substituted C1-C6 alkyl; each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.
    • 目的:提供作为白细胞介素-1β转换酶抑制剂的化合物。 还提供了治疗中风,再灌注损伤,阿尔茨海默病,志贺氏菌病,炎性疾病和含有该化合物的药学上可接受的组合物的方法。 构成:具有式(I)的式I化合物的化合物,其中R 1是R 3 CO-,R 3 SO 2 - ,各R aa独立地是氢,C 1 -C 6烷基或 - ( CH2)n芳基; R 2是 - (CRR)n - 芳基, - (CRR)n -X-芳基, - (CRR)n - 杂芳基 - (CRR)n X - 杂芳基 - (CRR)n-(取代杂芳基) CRR)n-(取代的 - 芳基), - (CRR)nX-(取代的 - 芳基), - (CRR)n-芳基 - - (CRR)n-芳基杂芳基, - (CRR) (CRR)n - 芳基, - (CRR)n-CH(芳基)2, - (CRR)n - 环烷基, - (CRR) , - (CRR)n取代的杂环,每个R独立地是氢,C 1 -C 6烷基,卤素或羟基; X是O或S; R 3是C 1 -C 6烷基,芳基杂芳基, - (CHR)n - 芳基, - (CHR)n - 杂芳基 - (CHR)n - 取代杂芳基, - (CHR)n-取代芳基 - (CRR) CH 2)n - 芳基,环烷基,取代的环烷基,杂环,取代的杂环,各R 1独立地是C 1 -C 6烷基,C 1 -C 6烷基芳基,芳基或氢; 每个J独立地为-CO 2 R b,-CONR b R b,-SO 2 NR a b R b b或-SO 2 R bb; 每个R b独立地是氢,C 1 -C 6烷基,芳基,取代的芳基; 芳基烷基,杂芳基烷基,取代的芳基烷基或取代的杂芳基烷基; R 4是氢,C 1 -C 6烷基, - 苯基,R 6是氢,C 1 -C 6烷基, - (CH 2)n芳基, - (CH 2)n CO 2 R a,羟基取代的C 1 -C 6烷基或咪唑取代的C 1 -C 6烷基; 每个n独立地为0至3,以及其药学上可接受的盐,酯,酰胺和前药。
    • 42. 发明公开
    • 티아졸릴-알라닌 잔기를 갖는 신규한 펩티드 유도체
    • 具有三氮唑胺残留的新型肽衍生物
    • KR1020000035930A
    • 2000-06-26
    • KR1019997001667
    • 1997-08-22
    • 시오노기세이야쿠가부시키가이샤
    • 스가와라다미오요시까와다까요시다다유끼오
    • C07K5/078
    • C07D417/06A61K38/00C07D207/28C07D277/24C07D417/14C07K5/0202C07K5/06139C07K5/0821C07K5/0825C07K5/1024
    • PURPOSE: Provided is a new peptide derivative having the residue of 3-(4-thiazolyl or 5-thiazolyl)-alanine and having an effect of activating the central nervous system. Pharmaceutically acceptable salt, or hydrate thereof are also provided. The compounds are useful as a medicament. CONSTITUTION: Provided are a peptide derivative of the formula (I), its pharmaceutically acceptable salt, or hydrate thereof wherein A is 4-thiazolyl or 5-thiazolyl wherein the nitrogen in the thiazolyl ring may be quarternary nitrogen which is formed with optionally substituted alkyl or alkenyl, X is a bond, oxygen, or sulfur, m is an integer of 0 to 4, Y is optionally substituted alkyl, optionally substituted carboxy, cyano, or the substituent; wherein R(1) and R(2) are independently hydrogen or optionally substituted alkyl, or R(1) and R(2) taken together with may form a non-aromatic heterocyclic ring the adjacent nitrogen which may contain oxygen, nitrogen, or sulfur and may be substituted, Z is the substituent; wherein R(3) is hydrogen, optionally substituted alkyl, optionally substituted carboxy, or optionally substituted acyl, R(4) and R(5) are each independently hydrogen or optionally substituted alkyl, and W is -(CH2)n- wherein n is 0, 1, 2, or 3, oxygen, sulfur, or optionally substituted imino, or the substituent.
    • 目的:提供具有3-(4-噻唑基或5-噻唑基) - 丙氨酸残基并具有活化中枢神经系统的作用的新肽衍生物。 还提供药学上可接受的盐或其水合物。 该化合物可用作药物。 构成:提供式(I)的肽衍生物,其药学上可接受的盐或水合物,其中A是4-噻唑基或5-噻唑基,其中噻唑环中的氮可以是与任选取代的烷基形成的季氮 或烯基,X为键,氧或硫,m为0至4的整数,Y为任选取代的烷基,任选取代的羧基,氰基或取代基; 其中R(1)和R(2)独立地是氢或任选取代的烷基,或者R(1)和R(2)可以形成非芳族杂环,相邻的氮可以含有氧,氮或 硫,可以被取代,Z是取代基; 其中R(3)为氢,任选取代的烷基,任选取代的羧基或任选取代的酰基,R(4)和R(5)各自独立地为氢或任选取代的烷基,W为 - (CH 2) 是0,1,2或3,氧,硫或任选取代的亚氨基,或取代基。